Pembrolizumab in Treating Patients With Small Bowel Adenocarcinoma That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Key facts

Sponsor

Academic and Community Cancer Research United

Principal Investigator

Robert McWilliams

Academic and Community Cancer Research United

Intervention

Laboratory Biomarker Analysis(other)

Enrollment

41 enrolled

Eligibility

18 years · All sexes

Timeline

2017 – 2024

Study locations (8)

• Mayo Clinic Hospital, Phoenix, Arizona, United States
• Mayo Clinic in Arizona, Scottsdale, Arizona, United States
• MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
• Mayo Clinic, Rochester, Minnesota, United States
• Washington University School of Medicine, St Louis, Missouri, United States
• Roswell Park Cancer Institute, Buffalo, New York, United States
• Rapid City Regional Hospital, Rapid City, South Dakota, United States
• M D Anderson Cancer Center, Houston, Texas, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Rare epithelial tumor of small intestine

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE2NCT04729322
  Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders
  M.D. Anderson Cancer Center
• RECRUITINGPHASE2NCT04205968
  Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
  SWOG Cancer Research Network

See all trials for Rare epithelial tumor of small intestine →